15 alternatives ranked by AI visibility score. Category: Synthetic Biology & DNA Synthesis.
Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, pharma, and AgBio.
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clini
Eikon Therapeutics is a drug discovery company that went public on Nasdaq in February 2026 (ticker: EIKN) with a $381 million IPO, armed with a proprietary RESOLFT super-resolution
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in
Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic d
Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapie
Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bact
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nas